# AbbVie Inc.: financial statements, quarterly

ABBV · NYSE · CIK 1551152 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/abbv.md) · [Financials](/companies/abbv/financials.md) · [Filings](/companies/abbv/filings.md) · [Insiders](/companies/abbv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/abbv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [13.9](/filings/0001551152-24-000040.md) | [14.3](/filings/0001551152-24-000011.md) | [12.3](/filings/0001551152-25-000029.md) | [14.5](/filings/0001551152-25-000040.md) | [14.5](/filings/0001551152-25-000049.md) | [15.1](/filings/0001551152-25-000020.md) | [13.3](/filings/0001551152-26-000017.md) | [15.4](/filings/0001551152-26-000026.md) | [15.8](/filings/0001551152-25-000049.md) | [16.6](/filings/0001551152-26-000008.md) | [15.0](/filings/0001551152-26-000017.md) | [17.0](/filings/0001551152-26-000026.md) |
| Cost of revenue | $bn | [6.5](/filings/0001551152-24-000040.md) | [5.7 d](/filings/0001551152-26-000008.md) | [4.1](/filings/0001551152-25-000029.md) | [4.2](/filings/0001551152-25-000040.md) | [4.2](/filings/0001551152-25-000049.md) | [4.4 d](/filings/0001551152-26-000008.md) | [4.0](/filings/0001551152-26-000017.md) | [4.3](/filings/0001551152-26-000026.md) | [5.3](/filings/0001551152-25-000049.md) | [4.6 d](/filings/0001551152-26-000008.md) | [4.2](/filings/0001551152-26-000017.md) | [4.3](/filings/0001551152-26-000026.md) |
| Gross profit | $bn | not reported | [8.6](/filings/0001551152-24-000011.md) | not reported | not reported | not reported | [10.7](/filings/0001551152-25-000020.md) | not reported | not reported | not reported | [12.1](/filings/0001551152-26-000008.md) | not reported | not reported |
| Selling, general and administrative | $bn | [3.4](/filings/0001551152-24-000040.md) | [3.2 d](/filings/0001551152-26-000008.md) | [3.3](/filings/0001551152-25-000029.md) | [3.4](/filings/0001551152-25-000040.md) | [4.2](/filings/0001551152-25-000049.md) | [3.9 d](/filings/0001551152-26-000008.md) | [3.3](/filings/0001551152-26-000017.md) | [3.3](/filings/0001551152-26-000026.md) | [3.6](/filings/0001551152-25-000049.md) | [3.9 d](/filings/0001551152-26-000008.md) | [3.6](/filings/0001551152-26-000017.md) | [3.6](/filings/0001551152-26-000026.md) |
| Operating income | $bn | [2.3](/filings/0001551152-24-000040.md) | [3.2 d](/filings/0001551152-26-000008.md) | [2.8](/filings/0001551152-25-000029.md) | [4.0](/filings/0001551152-25-000040.md) | [3.8](/filings/0001551152-25-000049.md) | [(1.5) d](/filings/0001551152-26-000008.md) | [3.7](/filings/0001551152-26-000017.md) | [4.9](/filings/0001551152-26-000026.md) | [1.9](/filings/0001551152-25-000049.md) | [4.5 d](/filings/0001551152-26-000008.md) | [4.0](/filings/0001551152-26-000017.md) | [6.4](/filings/0001551152-26-000026.md) |
| Interest expense | $bn | [0.6](/filings/0001551152-24-000040.md) | [0.6 d](/filings/0001551152-26-000008.md) | [0.7](/filings/0001551152-25-000029.md) | [0.7](/filings/0001551152-25-000040.md) | [0.7](/filings/0001551152-25-000049.md) | [0.7 d](/filings/0001551152-26-000008.md) | [0.7](/filings/0001551152-26-000017.md) | [0.7](/filings/0001551152-26-000026.md) | [0.7](/filings/0001551152-25-000049.md) | [0.7 d](/filings/0001551152-26-000008.md) | [0.7](/filings/0001551152-26-000017.md) | [0.7](/filings/0001551152-26-000026.md) |
| Income tax | $bn | [0.2](/filings/0001551152-24-000040.md) | [0.4 d](/filings/0001551152-26-000008.md) | [0.4](/filings/0001551152-25-000029.md) | [0.8](/filings/0001551152-25-000040.md) | [0.5](/filings/0001551152-25-000049.md) | [(2.2) d](/filings/0001551152-26-000008.md) | [0.4](/filings/0001551152-26-000017.md) | [0.6](/filings/0001551152-26-000026.md) | [0.5](/filings/0001551152-25-000049.md) | [0.9 d](/filings/0001551152-26-000008.md) | [0.3](/filings/0001551152-26-000017.md) | [0.7](/filings/0001551152-26-000026.md) |
| Net income | $bn | [1.8](/filings/0001551152-24-000040.md) | [0.8](/filings/0001551152-24-000011.md) | [1.4](/filings/0001551152-25-000029.md) | [1.4](/filings/0001551152-25-000040.md) | [1.6](/filings/0001551152-25-000049.md) | [(0.0)](/filings/0001551152-25-000020.md) | [1.3](/filings/0001551152-26-000017.md) | [0.9](/filings/0001551152-26-000026.md) | [0.2](/filings/0001551152-25-000049.md) | [1.8](/filings/0001551152-26-000008.md) | [0.7](/filings/0001551152-26-000017.md) | [3.6](/filings/0001551152-26-000026.md) |
| Diluted EPS | $ per share | [1.00](/filings/0001551152-24-000040.md) | [0.46](/filings/0001551152-24-000011.md) | [0.77](/filings/0001551152-25-000029.md) | [0.77](/filings/0001551152-25-000040.md) | [0.88](/filings/0001551152-25-000049.md) | [(0.02)](/filings/0001551152-25-000020.md) | [0.72](/filings/0001551152-26-000017.md) | [0.52](/filings/0001551152-26-000026.md) | [0.10](/filings/0001551152-25-000049.md) | [1.02](/filings/0001551152-26-000008.md) | [0.39](/filings/0001551152-26-000017.md) | [2.03](/filings/0001551152-26-000026.md) |
| Basic EPS | $ per share | [1.00](/filings/0001551152-24-000040.md) | [0.46](/filings/0001551152-24-000011.md) | [0.77](/filings/0001551152-25-000029.md) | [0.77](/filings/0001551152-25-000040.md) | [0.88](/filings/0001551152-25-000049.md) | [(0.02)](/filings/0001551152-25-000020.md) | [0.72](/filings/0001551152-26-000017.md) | [0.52](/filings/0001551152-26-000026.md) | [0.10](/filings/0001551152-25-000049.md) | [1.02](/filings/0001551152-26-000008.md) | [0.39](/filings/0001551152-26-000017.md) | [2.04](/filings/0001551152-26-000026.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [13.3](/filings/0001551152-23-000045.md) | [12.8](/filings/0001551152-25-000020.md) | [18.1](/filings/0001551152-24-000020.md) | [13.1](/filings/0001551152-24-000031.md) | [7.3](/filings/0001551152-24-000040.md) | [5.5](/filings/0001551152-26-000008.md) | [5.2](/filings/0001551152-25-000029.md) | [6.5](/filings/0001551152-25-000040.md) | [5.6](/filings/0001551152-25-000049.md) | [5.2](/filings/0001551152-26-000026.md) | [9.4](/filings/0001551152-26-000017.md) | [6.6](/filings/0001551152-26-000026.md) |
| Current assets | $bn | [33.2](/filings/0001551152-23-000045.md) | [33.0](/filings/0001551152-25-000020.md) | [38.9](/filings/0001551152-24-000020.md) | [33.8](/filings/0001551152-24-000031.md) | [27.8](/filings/0001551152-24-000040.md) | [25.6](/filings/0001551152-26-000008.md) | [27.7](/filings/0001551152-25-000029.md) | [29.3](/filings/0001551152-25-000040.md) | [28.5](/filings/0001551152-25-000049.md) | [29.1](/filings/0001551152-26-000026.md) | [33.5](/filings/0001551152-26-000017.md) | [33.7](/filings/0001551152-26-000026.md) |
| Total assets | $bn | [136](/filings/0001551152-23-000045.md) | [135](/filings/0001551152-25-000020.md) | [149](/filings/0001551152-24-000020.md) | [142](/filings/0001551152-24-000031.md) | [143](/filings/0001551152-24-000040.md) | [135](/filings/0001551152-26-000008.md) | [136](/filings/0001551152-25-000029.md) | [137](/filings/0001551152-25-000040.md) | [134](/filings/0001551152-25-000049.md) | [134](/filings/0001551152-26-000026.md) | [136](/filings/0001551152-26-000017.md) | [135](/filings/0001551152-26-000026.md) |
| Current liabilities | $bn | [34.8](/filings/0001551152-23-000045.md) | [37.8](/filings/0001551152-25-000020.md) | [41.5](/filings/0001551152-24-000020.md) | [41.9](/filings/0001551152-24-000031.md) | [43.1](/filings/0001551152-24-000040.md) | [38.7](/filings/0001551152-26-000008.md) | [36.4](/filings/0001551152-25-000029.md) | [39.8](/filings/0001551152-25-000040.md) | [39.4](/filings/0001551152-25-000049.md) | [43.3](/filings/0001551152-26-000026.md) | [42.1](/filings/0001551152-26-000017.md) | [41.6](/filings/0001551152-26-000026.md) |
| Long-term debt | $bn | not reported | [59.2](/filings/0001551152-24-000011.md) | not reported | not reported | not reported | [66.8](/filings/0001551152-25-000020.md) | not reported | not reported | not reported | [64.5](/filings/0001551152-26-000008.md) | not reported | not reported |
| Short-term borrowings | $bn | [0.0](/filings/0001551152-23-000045.md) | [0.0](/filings/0001551152-24-000020.md) | [0.0](/filings/0001551152-24-000020.md) | not reported | not reported | [0.0](/filings/0001551152-26-000008.md) | [1.6](/filings/0001551152-25-000029.md) | [5.6](/filings/0001551152-25-000040.md) | [3.8](/filings/0001551152-25-000049.md) | [2.5](/filings/0001551152-26-000026.md) | [0.0](/filings/0001551152-26-000017.md) | [0.0](/filings/0001551152-26-000026.md) |
| Shareholders' equity | $bn | [12.1](/filings/0001551152-23-000045.md) | [10.4](/filings/0001551152-25-000020.md) | [8.0](/filings/0001551152-24-000020.md) | [6.8](/filings/0001551152-24-000031.md) | [6.0](/filings/0001551152-24-000040.md) | [3.3](/filings/0001551152-26-000008.md) | [1.4](/filings/0001551152-25-000029.md) | [(0.2)](/filings/0001551152-25-000040.md) | [(2.6)](/filings/0001551152-25-000049.md) | [(3.3)](/filings/0001551152-26-000026.md) | [(6.7)](/filings/0001551152-26-000017.md) | [(5.9)](/filings/0001551152-26-000026.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [7,574 d](/filings/0001551152-24-000040.md) | [4,753 d](/filings/0001551152-26-000008.md) | [4,040](/filings/0001551152-25-000029.md) | [2,271 d](/filings/0001551152-25-000040.md) | [5,447 d](/filings/0001551152-25-000049.md) | [7,048 d](/filings/0001551152-26-000008.md) | [1,635](/filings/0001551152-26-000017.md) | [5,153 d](/filings/0001551152-26-000026.md) | [7,024 d](/filings/0001551152-25-000049.md) | [5,218 d](/filings/0001551152-26-000008.md) | [3,829](/filings/0001551152-26-000017.md) | [3,436 d](/filings/0001551152-26-000026.md) |
| Capital expenditure | $m | [219 d](/filings/0001551152-24-000040.md) | [205 d](/filings/0001551152-26-000008.md) | [193](/filings/0001551152-25-000029.md) | [241 d](/filings/0001551152-25-000040.md) | [249 d](/filings/0001551152-25-000049.md) | [291 d](/filings/0001551152-26-000008.md) | [235](/filings/0001551152-26-000017.md) | [269 d](/filings/0001551152-26-000026.md) | [381 d](/filings/0001551152-25-000049.md) | [329 d](/filings/0001551152-26-000008.md) | [265](/filings/0001551152-26-000017.md) | [322 d](/filings/0001551152-26-000026.md) |
| Dividends paid | $m | [2,627 d](/filings/0001551152-24-000040.md) | [2,626 d](/filings/0001551152-26-000008.md) | [2,772](/filings/0001551152-25-000029.md) | [2,750 d](/filings/0001551152-25-000040.md) | [2,751 d](/filings/0001551152-25-000049.md) | [2,752 d](/filings/0001551152-26-000008.md) | [2,925](/filings/0001551152-26-000017.md) | [2,910 d](/filings/0001551152-26-000026.md) | [2,911 d](/filings/0001551152-25-000049.md) | [2,911 d](/filings/0001551152-26-000008.md) | [3,086](/filings/0001551152-26-000017.md) | [3,070 d](/filings/0001551152-26-000026.md) |
| Share repurchases | $m | [4.0 d](/filings/0001551152-24-000040.md) | [3.0 d](/filings/0001551152-26-000008.md) | [1,324](/filings/0001551152-25-000029.md) | [9.0 d](/filings/0001551152-25-000040.md) | [17.0 d](/filings/0001551152-25-000049.md) | [358 d](/filings/0001551152-26-000008.md) | [961](/filings/0001551152-26-000017.md) | [12.0 d](/filings/0001551152-26-000026.md) | [4.0 d](/filings/0001551152-25-000049.md) | [3.0 d](/filings/0001551152-26-000008.md) | [1,489](/filings/0001551152-26-000017.md) | [9.0 d](/filings/0001551152-26-000026.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,776](/filings/0001551152-23-000045.md) | [1,776](/filings/0001551152-24-000020.md) | [1,771](/filings/0001551152-24-000031.md) | [1,771](/filings/0001551152-24-000040.md) | [1,773](/filings/0001551152-25-000029.md) | [1,771](/filings/0001551152-25-000040.md) | [1,772](/filings/0001551152-25-000049.md) | [1,772](/filings/0001551152-26-000017.md) | [1,771](/filings/0001551152-26-000026.md) | [1,772](/filings/0001551152-25-000049.md) | [1,774](/filings/0001551152-26-000017.md) | [1,771](/filings/0001551152-26-000026.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,767,117,285 at 2026-07-27, from the cover of the [10-Q filed 2026-08-03](/filings/0001551152-26-000026.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.